Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Profile Name | FGFR2 - BICC1 |
| Gene Variant Detail | |
| Relevant Treatment Approaches | FGFR Inhibitor (Pan) FGFR2 Inhibitor |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| Unknown unknown | renal cell carcinoma | not applicable | FGFR Inhibitor (Pan) | ODM-203 | Preclinical | Actionable | In a preclinical study, ODM-203 inhibited tumor growth and lung metastasis, and increased tumor microenvironment immune response in a VEGFR-dependent mouse renal carcinoma model (PMID: 30301864). | 30301864 |
| Unknown unknown | glioblastoma | not applicable | FGFR Inhibitor (Pan) | Ponatinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Iclusig (ponatinib) induced apoptosis and inhibited growth in glioblastoma cells in culture and in cell line xenograft models (PMID: 25378936). | 25378936 |
| Unknown unknown | chronic myeloid leukemia | not applicable | FGFR Inhibitor (Pan) | Ponatinib | FDA approved | Actionable | In a Phase II clinical trial which supported FDA approval, Iclusig (ponatinib) was effective in promoting disease regression in 52% of patients with accelerated phase chronic myeloid leukemia, 31% of patients with blast phase chronic myeloid leukemia, and 41% of patients with Philadelphia chromosome positive acute lymphoblastic leukemia (PMID: 23935038). | 23935038 detail... |
| Unknown unknown | chronic myeloid leukemia | not applicable | FGFR Inhibitor (Pan) | Ponatinib | Clinical Study | Actionable | In a meta-analysis, Iclusig (ponatinib) treatment was associated with increased rate of major molecular response compared with Gleevec (imatinib) (Odds Ratio (OR): 4.95 [0.97-25.19]), but not improved overall survival (OR: 2.00 [0.21-19.33]), and was associated with increased risk of vascular occlusive events (OR: 3.47 [1.23-9.78]) in patients with chronic myeloid leukemia (PMID: 26847662). | 26847662 |
| Unknown unknown | gastrointestinal stromal tumor | not applicable | FGFR Inhibitor (Pan) | Ponatinib | Phase II | Actionable | In a Phase II trial, Iclusig (ponatinib) demonstrated preliminary activity in patients with advanced gastrointestinal stromal tumor (J Clin Oncol (Meeting Abstracts) 2014 32: 10506). | detail... |
| Unknown unknown | lymphoid leukemia | not applicable | FGFR Inhibitor (Pan) | Ponatinib | FDA approved | Actionable | In a Phase II clinical trial which supported FDA approval, Iclusig (ponatinib) was effective in promoting disease regression in 52% of patients with accelerated phase chronic myeloid leukemia, 31% of patients with blast phase chronic myeloid leukemia, and 41% of patients with Philadelphia chromosome positive acute lymphoblastic leukemia (PMID: 23935038). | 23935038 detail... |
| Unknown unknown | Advanced Solid Tumor | not applicable | FGFR Inhibitor (Pan) | SSR128129E | Preclinical - Cell line xenograft | Actionable | In a preclinical study, SSR128129E inhibited tumor growth in several solid tumor cell line xenograft models (PMID: 23597562). | 23597562 |
| Unknown unknown | melanoma | not applicable | FGFR Inhibitor (Pan) | Dovitinib | Phase Ib/II | Actionable | In a Phase I/II study, Dovitinib (TKI258) was demonstrated safe, but of limited clinical benefit in patients with advanced melanoma (PMID: 21976540). | 21976540 |
| Unknown unknown | adenoid cystic carcinoma | not applicable | FGFR Inhibitor (Pan) | Dovitinib | Phase II | Actionable | In a Phase II trial, Dovitinib (TKI258) treatment was tolerated and demonstrated limited clinical activity in patients with adenoid cystic carcinoma, resulting in partial response in 5.9% (2/34) of patients, suppression of overall tumor growth rate, and a median progression-free survival of 8.2 months (PMID: 28377480). | 28377480 |
| Unknown unknown | glioblastoma | not applicable | FGFR Inhibitor (Pan) | Dovitinib | Phase I | Actionable | In a Phase I trial, Dovitinib (TKI258) treatment resulted in a progression free survival rate at 6 months of 16.7% (2/12) in patients with recurrent glioblastoma (PMID: 27100354). | 27100354 |
| Unknown unknown | gastrointestinal stromal tumor | not applicable | FGFR Inhibitor (Pan) | Dovitinib | Phase II | Actionable | In a Phase II clinical trial, Dovitinib (TKI258) demonstrated safety and efficacy in heavily pretreated patients with advanced GISTs (PMID: 24084771). | 24084771 |
| Unknown unknown | renal cell carcinoma | not applicable | FGFR Inhibitor (Pan) | Dovitinib | Phase III | Actionable | In a Phase III clinical trial, Dovitinib (TKI258) demonstrated efficacy equivalent to Nexavar (sorafenib) in metastatic renal cell carcinoma patients (PMID: 24556040). | 24556040 |
| Unknown unknown | renal cell carcinoma | not applicable | FGFR Inhibitor (Pan) | Dovitinib | Phase I | Actionable | In a Phase I trial, Dovitinib (TKI258) demonstrated safety and efficacy resulting in 10% (2/20) partial response and 60% (12/20) stable disease in renal cell carcinoma patients (PMID: 23339124). | 23339124 |
| Unknown unknown | Advanced Solid Tumor | not applicable | FGFR Inhibitor (Pan) | PRN1371 | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, PRN1371 inhibited proliferation of various FGFR-driven tumor cell lines in culture and inhibited tumor growth in a variety of patient-derived xenograft models with FGFR pathway alterations (AACR; 2016. Abstract nr 1249). | detail... |
| Unknown unknown | lung non-small cell carcinoma | not applicable | FGFR Inhibitor (Pan) | PRN1371 | Preclinical - Pdx | Actionable | In a preclinical study, PRN1371 treatment resulted in tumor regression in PDX models of non-small cell lung cancer (Eu J Cancer 2014 Vol 50, Suppl 6:157). | detail... |
| Unknown unknown | glioblastoma | not applicable | FGFR Inhibitor (Pan) | PRN1371 | Preclinical - Pdx | Actionable | In a preclinical study, PRN1371 treatment resulted in tumor regression in PDX models of glioblastoma (Eu J Cancer 2014 Vol 50, Suppl 6:157). | detail... |
| Unknown unknown | esophageal cancer | not applicable | FGFR Inhibitor (Pan) | Futibatinib | Phase I | Actionable | In a Phase I trial, TAS-120 treatment resulted in clinical response in an esophageal cancer patient (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 372PD). | detail... |
| Unknown unknown | urinary bladder cancer | not applicable | FGFR Inhibitor (Pan) | Futibatinib | Phase I | Actionable | In a Phase I trial, TAS-120 treatment resulted in stable disease over 24 weeks in a bladder cancer patient (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 372PD). | detail... |
| Unknown unknown | Advanced Solid Tumor | not applicable | FGFR Inhibitor (Pan) | Futibatinib | Phase I | Actionable | In a Phase I trial, TAS-120 treatment resulted in clinical response in 5.5% (2/36) and stable disease over 24 weeks in 5.5% (2/36) of patients with advanced solid tumors (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 372PD). | detail... |
| Unknown unknown | lung non-small cell carcinoma | not applicable | FGFR Inhibitor (Pan) | Carboplatin + Lenvatinib + Paclitaxel | Phase I | Actionable | In a Phase I trial of patients with advanced or metastatic NSCLC, treatment with Lenvima (lenvatinib) in combination with Paraplatin (carboplatin) and Taxol (paclitaxel) was tolerated and demonstrated anti-tumor activity (PMID: 23860537). | 23860537 |
| Unknown unknown | renal cell carcinoma | not applicable | FGFR Inhibitor (Pan) | Everolimus + Lenvatinib | FDA approved | Actionable | In a Phase II clinical trial that supported FDA approval, treatment with the combination of Lenvima (lenvatinib) and Afinitor (everolimus) resulted in a prolonged median progression-free survival of 14.6 months, compared to 5.5 months for Afinitor (everolimus) alone in patients with metastatic renal cell carcinoma who had progressed after one previous VEGF-targeted therapy (PMID: 26482279; NCT01136733). | 26482279 detail... |
| Unknown unknown | renal cell carcinoma | not applicable | FGFR Inhibitor (Pan) | Everolimus + Lenvatinib | Phase Ib/II | Actionable | In a Phase Ib clinical trial, the combination of Lenvima (lenvatinib) and Afinitor (everolimus) demonstrated safety, and resulted in partial response in 30% (6/20) of patients with metastatic renal cell carcinoma (PMID: 24190702). | 24190702 |
| Unknown unknown | colon cancer | not applicable | FGFR Inhibitor (Pan) | Lenvatinib | Preclinical | Actionable | In a preclinical study, Lenvima (lenvatinib) induced apoptosis and inhibited proliferation of colorectal cancer cells in culture (PMID: 24255582). | 24255582 |
| Unknown unknown | Advanced Solid Tumor | not applicable | FGFR Inhibitor (Pan) | Lenvatinib | Phase I | Actionable | In a Phase I trial, Lenvima (lenvatinib) demonstrated safety and preliminary anti-tumor activity in patients with advanced solid tumors (PMID: 22516948). | 22516948 |
| Unknown unknown | Advanced Solid Tumor | not applicable | FGFR Inhibitor (Pan) | Lenvatinib | Phase I | Actionable | In a Phase I trial, Lenvima (lenvatinib) treatment resulted in partial response in 11.7% (9/77) and stable disease in 51.9% (40/77) of patients with advanced solid tumors (PMID: 26169970). | 26169970 |
| Unknown unknown | thyroid gland medullary carcinoma | not applicable | FGFR Inhibitor (Pan) | Lenvatinib | Phase II | Actionable | In a Phase II trial, advanced medullary thyroid cancer patients experienced an objective response rate of 36% (21/59, all partial responses) and median progression free survival was 9 months when treated with Lenvima (lenvatinib) (PMID: 26311725). | 26311725 |
| Unknown unknown | renal cell carcinoma | not applicable | FGFR Inhibitor (Pan) | Lenvatinib | Phase I | Actionable | In a Phase I trial, Lenvima (lenvatinib) was demonstrated to be well tolerated and displayed anti-tumor activity in patients with melanoma and renal cell carcinoma (PMID: 22516948). | 22516948 |
| Unknown unknown | thyroid gland cancer | not applicable | FGFR Inhibitor (Pan) | Lenvatinib | Phase II | Actionable | In a Phase II clinical trial, Lenvima (lenvatinib) demonstrated partial response in 36% (21/59) of patients, partial response or stable disease in 80% (47/59), and median progression free survival of 9 months in patients with advanced medullary thyroid cancer (PMID: 26311725). | 26311725 |
| Unknown unknown | thyroid gland cancer | not applicable | FGFR Inhibitor (Pan) | Lenvatinib | FDA approved | Actionable | In a Phase III trial (SELECT) that supported FDA approval, treatment with Lenvima (lenvatinib) improved progression free survival (18.3 vs 3.6 months, HR=0.21, p<0.001) and response rates (64.8% vs 1.5%, p<0.001) compared to placebo in patients with radioiodine-refractory differentiated thyroid cancer (PMID: 25671254; NCT01321554). | 25671254 detail... |
| Unknown unknown | hepatocellular carcinoma | not applicable | FGFR Inhibitor (Pan) | Lenvatinib | Phase I | Actionable | In a Phase I trial, Lenvima (lenvatinib) resulted in safety and preliminary efficacy in patients with hepatocellular carcinoma, demonstrating a partial response in 15% (3/20) of patients and tumor regression in 70% (14/20) (PMID: 26500236). | 26500236 |
| Unknown unknown | hepatocellular carcinoma | not applicable | FGFR Inhibitor (Pan) | Lenvatinib | Case Reports/Case Series | Actionable | In a Phase I trial, a hepatocellular carcinoma patient treated with Lenvima (lenvatinib) following the discontinuation of CEBPA-51 (MTL-CEBPA) treatment achieved a partial response, but demonstrated progression at 6 months following treatment (PMID: 32357963; NCT02716012). | 32357963 |
| Unknown unknown | hepatocellular carcinoma | not applicable | FGFR Inhibitor (Pan) | Lenvatinib | FDA approved | Actionable | In a Phase III trial (REFLECT) that supported FDA approval, Lenvima (lenvatinib) demonstrated activity comparable to Nexavar (sorafenib), resulted in a median survival time of 13.6 months in patients with unresectable hepatocellular carcinoma (PMID: 29433850; NCT01761266). | detail... 29433850 |
| Unknown unknown | hepatocellular carcinoma | not applicable | FGFR Inhibitor (Pan) | Lenvatinib | Phase II | Actionable | In a Phase II trial, Lenvima (lenvatinib) treatment resulted in partial response in 37% (17/46) and stable disease in 41% (19/46) of patients with advanced hepatocellular carcinoma, and a median overall survival of 18.7 months (PMID: 27704266). | 27704266 |
| Unknown unknown | sarcoma | not applicable | FGFR Inhibitor (Pan) | Lenvatinib | Phase I | Actionable | In a Phase I trial, Lenvima (lenvatinib) demonstrated safety and anti-tumor activity in patients with advanced solid tumors, including partial responses in patients with soft-tissue sarcoma (PMID: 22516948). | 22516948 |
| Unknown unknown | thyroid gland papillary carcinoma | not applicable | FGFR Inhibitor (Pan) | Lenvatinib | Clinical Study | Actionable | In a clinical study, Lenvima (lenvatinib) treatment resulted in prolonged response in a papillary thyroid carcinoma patient whose disease progressed despite 3 prior therapies including Nexavar (sorafenib), Sutent (sunitinib), and Votrient (pazopanib) (PMID: 29167691). | 29167691 |
| Unknown unknown | melanoma | not applicable | FGFR Inhibitor (Pan) | Lenvatinib | Phase I | Actionable | In a Phase I trial, Lenvima (lenvatinib) was demonstrated to be well tolerated and displayed anti-tumor activity in patients with melanoma and renal cell carcinoma (PMID: 22516948). | 22516948 |
| Unknown unknown | lung non-small cell carcinoma | not applicable | FGFR Inhibitor (Pan) | Lenvatinib | Phase I | Actionable | In a Phase I clinical trial, Lenvima (lenvatinib) demonstrated anti-tumor activity in patients with several advanced solid tumor types, including patients with non-small cell lung cancer (PMID: 26169970). | 26169970 |
| Unknown unknown | endometrial cancer | not applicable | FGFR Inhibitor (Pan) | Lenvatinib + Pembrolizumab | Phase Ib/II | Actionable | Ina Phase Ib/II trial, Lenvima (lenvatinib) and Keytruda (pembrolizumab) combination treatment demonstrated safety and efficacy, resulted in an objective response rate of 52% (12/23) in patients with metastatic endometrial cancer, with a median duration of response not evaluable, and a median progression-free survival of 9.7 months (PMID: 31961766; NCT02501096). | 31961766 |
| Unknown unknown | transitional cell carcinoma | not applicable | FGFR Inhibitor (Pan) | Lenvatinib + Pembrolizumab | Phase Ib/II | Actionable | Ina Phase Ib/II trial, Lenvima (lenvatinib) and Keytruda (pembrolizumab) combination treatment demonstrated safety and efficacy, resulted in an objective response rate of 25% (5/20) in patients with metastatic urothelial cancer, with a median duration of response not evaluable, and a median progression-free survival of 5.4 months (PMID: 31961766; NCT02501096). | 31961766 |
| Unknown unknown | endometrial carcinoma | not applicable | FGFR Inhibitor (Pan) | Lenvatinib + Pembrolizumab | FDA approved | Actionable | In a Phase II trial (Study 111/KEYNOTE-146) that supported FDA approval, Lenvima (lenvatinib) and Keytruda (pembrolizumab) combination treatment resulted in an objective response rate of 35.6% (16/45) in patients with endometrial carcinoma that was not MSI-H or dMMR (PMID: 30922731; NCT02501096). | detail... detail... 30922731 |
| Unknown unknown | head and neck squamous cell carcinoma | not applicable | FGFR Inhibitor (Pan) | Lenvatinib + Pembrolizumab | Phase Ib/II | Actionable | Ina Phase Ib/II trial, Lenvima (lenvatinib) and Keytruda (pembrolizumab) combination treatment demonstrated safety and efficacy, resulted in an objective response rate of 46% (10/22) in patients with metastatic head and neck squamous cell carcinoma, with a median duration of response of 8.2 months, and a median progression-free survival of 4.7 months (PMID: 31961766; NCT02501096). | 31961766 |
| Unknown unknown | melanoma | not applicable | FGFR Inhibitor (Pan) | Lenvatinib + Pembrolizumab | Phase Ib/II | Actionable | Ina Phase Ib/II trial, Lenvima (lenvatinib) and Keytruda (pembrolizumab) combination treatment demonstrated safety and efficacy, resulted in an objective response rate of 48% (10/21) in patients with metastatic melanoma, with a median duration of response of 12.5 months, and a median progression-free survival of 5.5 months (PMID: 31961766; NCT02501096). | 31961766 |
| Unknown unknown | lung non-small cell carcinoma | not applicable | FGFR Inhibitor (Pan) | Lenvatinib + Pembrolizumab | Phase Ib/II | Actionable | In a Phase Ib/II trial, Lenvima (lenvatinib) and Keytruda (pembrolizumab) combination treatment demonstrated safety and efficacy, resulted in an objective response rate of 33% (7/21) in patients with metastatic non-small cell lung cancer, with a median duration of response of 10.9 months, and a median progression-free survival of 5.9 months (PMID: 31961766; NCT02501096). | 31961766 |
| Unknown unknown | stomach cancer | not applicable | FGFR Inhibitor (Pan) | Lenvatinib + Pembrolizumab | Phase II | Actionable | In a Phase II trial (EPOC1706), the combination of Lenvima (lenvatinib) and Keytruda (pembrolizumab) treatment in patients with either stomach cancer or gastroesophageal junction cancer resulted in a 69% (20/29) objective response rate, a disease control rate of 100% (29/29), a median progression-free survival of 7.1 months, and a median overall survival that had not yet been reached, and 8 patients were still experiencing an ongoing response at data cut-off (PMID: 32589866; NCT03609359). | 32589866 |
| Unknown unknown | gastroesophageal junction adenocarcinoma | not applicable | FGFR Inhibitor (Pan) | Lenvatinib + Pembrolizumab | Phase II | Actionable | In a Phase II trial (EPOC1706), the combination of Lenvima (lenvatinib) and Keytruda (pembrolizumab) treatment in patients with either stomach cancer or gastroesophageal junction cancer resulted in a 69% (20/29) objective response rate, a disease control rate of 100% (29/29), a median progression-free survival of 7.1 months, and a median overall survival that had not yet been reached, and 8 patients were still experiencing an ongoing response at data cut-off (PMID: 32589866; NCT03609359). | 32589866 |
| Unknown unknown | renal cell carcinoma | not applicable | FGFR Inhibitor (Pan) | Lenvatinib + Pembrolizumab | Phase Ib/II | Actionable | Ina Phase Ib/II trial, Lenvima (lenvatinib) and Keytruda (pembrolizumab) combination treatment demonstrated safety and efficacy, resulted in an objective response rate of 70% (21/30) in patients with metastatic renal cell carcinoma, with a median duration of response of 20.0 months, and a median progression-free survival of 19.8 months (PMID: 31961766; NCT02501096). | 31961766 |
| Unknown unknown | urinary bladder cancer | not applicable | FGFR Inhibitor (Pan) | ASP5878 | Phase I | Actionable | In a Phase I trial, ASP5878 demonstrated safety and some preliminary efficacy in patients with advanced solid tumors, including a bladder cancer patient with an FGFR gene mutation (AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A165). | detail... |
| Unknown unknown | Advanced Solid Tumor | not applicable | FGFR Inhibitor (Pan) | ASP5878 | Phase I | Actionable | In a Phase I trial, ASP5878 demonstrated safety and some preliminary efficacy in patients with advanced solid tumors, including a bladder cancer patient with an FGFR gene mutation (AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A165). | detail... |
| Unknown unknown | Advanced Solid Tumor | not applicable | FGFR Inhibitor (Pan) | Alpelisib + Infigratinib | Phase I | Actionable | In a Phase Ib trial, Infigratinib (BGJ398) and Alpelisib (BYL719) combination treatment resulted in partial response in 25% (8/32) of patients with advanced solid tumors, including urothelial, head and neck, melanoma, and anal cancer (J Clin Oncol 34, 2016 (suppl; abstr 2500)). | detail... |
| Unknown unknown | alveolar rhabdomyosarcoma | not applicable | FGFR Inhibitor (Pan) | Infigratinib | Preclinical - Pdx | Actionable | In a preclinical study, Infigratinib (BGJ398) resulted in antitumor activity in an alveolar rhabdomyosarcoma patient derived xenograft (PDX) model (PMID: 24687871). | 24687871 |
| Unknown unknown | Advanced Solid Tumor | not applicable | FGFR Inhibitor (Pan) | Erdafitinib | Phase I | Actionable | In a Phase I study, Balversa (erdafitinib) displayed safety and efficacy in advanced solid tumor patients (J Clin Oncol 32:5s, 2014 (suppl; abstr 2501)). | detail... |
| Unknown unknown | ovarian cancer | not applicable | FGFR Inhibitor (Pan) | Carboplatin + Nintedanib + Paclitaxel | Phase III | Actionable | In a Phase III clinical trial, patients with advanced ovarian cancer treated with Ofev (nintedanib), in combination with Paraplatin (carboplatin) and Taxol (paclitaxel), experienced a progression free survival of 17.2 months versus 16.6 months in patients treated with a combination of placebo, carboplatin, and paclitaxel in first-line treatment (PMID: 26590673). | 26590673 |
| Unknown unknown | lung adenocarcinoma | not applicable | FGFR Inhibitor (Pan) | Docetaxel + Nintedanib | Phase III | Actionable | In a Phase III trial, the combination of Ofev (nintedanib) and Taxotere (docetaxel) resulted in an improved overall survival in lung adenocarcinoma patients, particularly those patients with shorter time to progression after first line chemotherapy, which included measures that were time from start or time from end of first line chemotherapy (PMID: 28702806). | 28702806 |
| Unknown unknown | lung non-small cell carcinoma | not applicable | FGFR Inhibitor (Pan) | Docetaxel + Nintedanib | Phase III | Actionable | In a Phase III clinical trial, the combination of Ofev (nintedanib) and Taxotere (docetaxel) resulted in improved progression-free survival and overall survival compared to placebo plus Taxotere (docetaxel) in non-small cell lung cancer patients (PMID: 24411639). | 24411639 |
| Unknown unknown | pancreatic cancer | not applicable | FGFR Inhibitor (Pan) | Nintedanib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Nintedanib, alone or with chemotherapy, inhibited tumor growth in cell line xenograft models of lung and pancreatic cancer but not in cell culture (PMID: 23729403). | 23729403 |
| Unknown unknown | colorectal cancer | not applicable | FGFR Inhibitor (Pan) | Nintedanib | Phase I | Actionable | In a Phase I trial, Ofev (nintedanib) demonstrated safety and efficacy in patients with advanced colorectal cancer (PMID: 25012508). | 25012508 |
| Unknown unknown | Advanced Solid Tumor | not applicable | FGFR Inhibitor (Pan) | Nintedanib | Phase I | Actionable | In a Phase I trial, Ofev (nintedanib) demonstrated safety and some preliminary efficacy in patients with advanced solid tumors (PMID: 25795637). | 25795637 |
| Unknown unknown | ovarian cancer | not applicable | FGFR Inhibitor (Pan) | Nintedanib | Phase I | Actionable | In a Phase I clinical trial, Vargatef (nintedanib) demonstrated safety in patients with ovarian cancers, clinical trials to determine efficacy in these patients are ongoing (PMID: 19889612). | 19889612 |
| Unknown unknown | gastric adenocarcinoma | not applicable | FGFR Inhibitor (Pan) | Nintedanib | Phase II | Actionable | In a Phase II trial, Ofev (nintedanib) was well tolerated and the study met its primary endpoint, resulted in progression-free survival at 6-months in 19% (6/32) of patients with esophageal/GEJ (n=17) or gastric (n=15) adenocarcinoma, with a median follow-up of 14.5 months and a median overall survival of 14.2 months (PMID: 30952642; NCT02234596). | 30952642 |
| Unknown unknown | esophagus adenocarcinoma | not applicable | FGFR Inhibitor (Pan) | Nintedanib | Phase II | Actionable | In a Phase II trial, Ofev (nintedanib) was well tolerated and the study met its primary endpoint, resulted in progression-free survival at 6-months in 19% (6/32) of patients with esophageal/GEJ (n=17) or gastric (n=15) adenocarcinoma, with a median follow-up of 14.5 months and a median overall survival of 14.2 months (PMID: 30952642; NCT02234596). | 30952642 |
| Unknown unknown | pancreatic endocrine carcinoma | not applicable | FGFR Inhibitor (Pan) | Nintedanib | Preclinical | Actionable | In a preclinical study, Ofev (nintedanib) induced tumor cell apoptosis, decreased microvessel density, inhibited tumor growth, and improved survival in transgenic mouse models of pancreatic neuroendocrine carcinoma (PMID: 26206868). | 26206868 |
| Unknown unknown | gastroesophageal junction adenocarcinoma | not applicable | FGFR Inhibitor (Pan) | Nintedanib | Phase II | Actionable | In a Phase II trial, Ofev (nintedanib) was well tolerated and the study met its primary endpoint, resulted in progression-free survival at 6-months in 19% (6/32) of patients with esophageal/GEJ (n=17) or gastric (n=15) adenocarcinoma, with a median follow-up of 14.5 months and a median overall survival of 14.2 months (PMID: 30952642; NCT02234596). | 30952642 |
| Unknown unknown | Indication other than cancer | not applicable | FGFR Inhibitor (Pan) | Nintedanib | FDA approved | Actionable | Ofev (nintedanib) is FDA approved for use in patients with idiopathic pulmonary fibrosis (FDA.gov). | detail... detail... |
| Unknown unknown | brain glioma | not applicable | FGFR Inhibitor (Pan) | Nintedanib | Phase II | Actionable | In a Phase II clinical trial, Ofev (nintedanib) failed to show any efficacy in patients with recurrent high-grade glioma, regardless of prior bevacizumab therapy (PMID: 25338318). | 25338318 |
| Unknown unknown | lung adenocarcinoma | not applicable | FGFR Inhibitor (Pan) | Nintedanib | Phase III | Actionable | In a Phase III clinical trial, the combination of Ofev (nintedanib) and Taxotere (docetaxel) improved progression-free survival and overall survival in patients with lung adenocarcinoma compared to Taxotere (docetaxel) alone (PMID: 24411639). | 24411639 |
| Unknown unknown | lung cancer | not applicable | FGFR Inhibitor (Pan) | Nintedanib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Nintedanib, alone or with chemotherapy, inhibited tumor growth in cell line xenograft models of lung and pancreatic cancer but not in cell culture (PMID: 23729403). | 23729403 |
| Unknown unknown | stomach cancer | not applicable | FGFR Inhibitor (Pan) | LY2874455 | Phase I | Actionable | In a Phase I trial, gastric cancer patients treated with LY2874455 demonstrated some efficacy, including one patient with a partial response, 12 patients with stable disease after two cycles, and 4 patients with stable disease after four cycles of treatment, and had a median progression free survival of 62 days (PMID: 28589492). | 28589492 |
| Unknown unknown | thyroid gland cancer | not applicable | FGFR Inhibitor (Pan) | LY2874455 | Phase I | Actionable | In a Phase I trial, a patient with thyroid cancer demonstrated stable disease when treated with LY2874455 (PMID: 28589492). | 28589492 |
| Unknown unknown | lung non-small cell carcinoma | not applicable | FGFR Inhibitor (Pan) | LY2874455 | Phase I | Actionable | In a Phase I trial, 92% (11/12) of patients with non-small cell lung carcinoma demonstrated stable disease after two cycles of LY2874455, however, after four cycles, all patients had either progressed or discontinued the study (PMID: 28589492; NCT01212107). | 28589492 |
| Unknown unknown | urinary bladder cancer | not applicable | FGFR Inhibitor (Pan) | MPT0L145 | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with MPT0L145 resulted in decreased cell viability in bladder cancer cell lines in culture (PMID: 29222162). | 29222162 |
| Unknown unknown | peritoneum cancer | not applicable | FGFR2 Inhibitor | ENMD-2076 | Phase II | Actionable | In a Phase II clinical trial, ENMD-2076 demonstrated efficacy in patients with recurrent, platinum-resistant ovarian, fallopian tube or peritoneal cancers (PMID: 22921155). | 22921155 |
| Unknown unknown | acute myeloid leukemia | not applicable | FGFR2 Inhibitor | ENMD-2076 | Phase I | Actionable | In a Phase I trial, treatment with ENMD-2076 resulted in a 25% (4/16) overall response rate in patients with acute myeloid leukemia as well as three patients achieving a complete response (with incomplete count recovery) and one patient with a morphological leukemia free state (PMID: 27406088). | 27406088 |
| Unknown unknown | ovarian clear cell carcinoma | no benefit | FGFR2 Inhibitor | ENMD-2076 | Phase II | Actionable | In a Phase II trial, ENMD-2076 did not meet efficacy standard, resulted in partial response in 7.9% (3/38) and stable disease in 68.4% (26/38) of patients with recurrent ovarian clear cell carcinoma, with an overall 6-month progression-free survival rate of 22% (PMID: 30108107). | 30108107 |
| Unknown unknown | fallopian tube cancer | not applicable | FGFR2 Inhibitor | ENMD-2076 | Phase II | Actionable | In a Phase II clinical trial, ENMD-2076 demonstrated efficacy in patients with recurrent, platinum-resistant ovarian, fallopian tube or peritoneal cancers (PMID: 22921155). | 22921155 |
| Unknown unknown | ovarian cancer | not applicable | FGFR2 Inhibitor | ENMD-2076 | Phase II | Actionable | In a Phase II clinical trial, ENMD-2076 demonstrated efficacy in patients with recurrent, platinum-resistant ovarian, fallopian tube or peritoneal cancers (PMID: 22921155). | 22921155 |
| Unknown unknown | papillary renal cell carcinoma | not applicable | FGFR2 Inhibitor | Abexinostat + Pazopanib | Phase Ib/II | Actionable | In a Phase Ib/II trial, 17% (1/6) of patients with papillary renal cell carcinoma demonstrated a response to the combination of Abexinostat (PCI-24781) and Votrient (pazopanib) (PMID: 28221861). | 28221861 |
| Unknown unknown | clear cell renal cell carcinoma | not applicable | FGFR2 Inhibitor | Abexinostat + Pazopanib | Phase Ib/II | Actionable | In a Phase Ib/II trial, 31% (5/16) of renal clear cell carcinoma patients demonstrated a response to the combination of Abexinostat (PCI-24781) and Votrient (pazopanib) (PMID: 28221861). | 28221861 |
| Unknown unknown | Advanced Solid Tumor | not applicable | FGFR2 Inhibitor | Abexinostat + Pazopanib | Phase Ib/II | Actionable | In a Phase Ib/II trial, the combination of Abexinostat (PCI-24781) and Votrient (pazopanib) in advanced solid tumor patients resulted in a clinical benefit rate of 37% (16/43), a median response duration of 9.1 months, and 8 patients of 43 achieved stable disease or durable response for greater than 12 months (PMID: 28221861). | 28221861 |
| Unknown unknown | renal cell carcinoma | not applicable | FGFR2 Inhibitor | Abexinostat + Pazopanib | Phase Ib/II | Actionable | In a Phase Ib/II trial, 27% (6/22) of renal cell carcinoma patients demonstrated a response when treated with a combination of Abexinostat (PCI-24781) and Votrient (pazopanib) (PMID: 28221861). | 28221861 |
| Unknown unknown | Advanced Solid Tumor | not applicable | FGFR2 Inhibitor | Carboplatin + Paclitaxel + Pazopanib | Phase I | Actionable | In a Phase I study, Votrient (pazopanib) in combination with Taxol (paclitaxel) and Paraplatin (carboplatin) demonstrated efficacy in solid tumors (PMID: 22679111). | 22679111 |
| Unknown unknown | angiosarcoma | not applicable | FGFR2 Inhibitor | Carotuximab + Pazopanib | Phase Ib/II | Actionable | In a Phase I/II trial, TRC105 and Votrient (pazopanib) combination therapy resulted complete response in 40% (2/5) of angiosarcoma patients (J Clin Oncol 34, 2016 (suppl; abstr 11016)). | detail... |
| Unknown unknown | sarcoma | not applicable | FGFR2 Inhibitor | Carotuximab + Pazopanib | Phase Ib/II | Actionable | In a Phase I/II trial, TRC105 and Votrient (pazopanib) combination therapy resulted in a median progression free survival of 3.95 months and ongoing complete response in 4% (3/81) of soft tissue sarcoma patients (J Clin Oncol 34, 2016 (suppl; abstr 11016)). | detail... |
| Unknown unknown | head and neck squamous cell carcinoma | not applicable | FGFR2 Inhibitor | Cetuximab + Pazopanib | Phase Ib/II | Actionable | In a Phase Ib clinical trial, combined therapy, Votrient (pazopanib) and Erbitux (cetuximab), was well tolerated in head and neck squamous cell carcinoma patients with metastatic or resistant disease, and resulted in a 6% (2/31) complete response rate, a 29% (9/31) partial response rate, a median time to progression of 5.5 months, and a median overall survival of 9.5 months (PMID: 30001987; NCT01716416). | 30001987 |
| Unknown unknown | clear cell renal cell carcinoma | no benefit | FGFR2 Inhibitor | Everolimus + Pazopanib | Phase II | Actionable | In a Phase II trial, alternating treatment with Votrient (pazopanib) and Afinitor (everolimus) did not improve 1-year progression free survival rate (45% vs 32%) or time to progression/death (7.4 vs 9.4 months) compared to continuous Votrient (pazopanib) treatment in patients with renal clear cell carcinoma (PMID: 27918762). | 27918762 |
| Unknown unknown | Advanced Solid Tumor | not applicable | FGFR2 Inhibitor | Gemcitabine + Pazopanib | Phase I | Actionable | In a Phase I study, Votrient (pazopanib) administered with Gemzar (gemcitabine) was shown to be tolerated in patients with advanced solid tumors, and resulted in one partial response (metastatic melanoma) and prolonged disease stabilization in three patients (metastatic melanoma, cholangiocarcinoma, and colorectal carcinoma) (PMID: 23064954). | 23064954 |
| Unknown unknown | melanoma | not applicable | FGFR2 Inhibitor | Gemcitabine + Pazopanib | Phase I | Actionable | In a Phase I study, Votrient (pazopanib) administered with Gemzar (gemcitabine) was shown to be tolerated with one partial response (metastatic melanoma) and prolonged disease stabilization in three patients (metastatic melanoma, cholangiocarcinoma, and colorectal carcinoma) (PMID: 23064954). | 23064954 |
| Unknown unknown | Advanced Solid Tumor | not applicable | FGFR2 Inhibitor | Paclitaxel + Pazopanib | Phase I | Actionable | In a Phase I trial, the combination of Votrient (pazopanib) and Taxol (paclitaxel) demonstrated safety and resulted in partial response in 36% (10/28) and stable disease in 36% (10/28) of patients with advanced solid tumors (PMID: 25504632). | 25504632 |
| Unknown unknown | transitional cell carcinoma | not applicable | FGFR2 Inhibitor | Paclitaxel + Pazopanib | Phase II | Actionable | In a Phase II trial, patients with urothelial carcinoma treated with the combination of Taxol (paclitaxel) and Votrient (pazopanib) demonstrated an overall response rate of 54% (15/28), in which 11% (3/28) experienced a complete response and 43% (12/28) experienced stable disease (PMID: 27068017). | 27068017 |
| Unknown unknown | uterine corpus sarcoma | not applicable | FGFR2 Inhibitor | Pazopanib | Clinical Study | Actionable | In a retrospective clinical study, Votrient (pazopanib) treatment resulted in objective response in 29% (10/35) and stable disease in 31% (11/35) of patients with uterine sarcoma, with median progression-free survival of 5.8 months and overall survival of 20.0 months (PMID: 29185261). | 29185261 |
| Unknown unknown | breast cancer | not applicable | FGFR2 Inhibitor | Pazopanib | Phase II | Actionable | In a Phase II trial, Votrient (pazopanib) displayed safety and some efficacy in breast cancer patients (PMID: 20682606). | 20682606 |
| Unknown unknown | sarcoma | not applicable | FGFR2 Inhibitor | Pazopanib | Clinical Study | Actionable | In a retrospective study, Votrient (pazopanib) treatment resulted in median progression free survival of 15.4 weeks and median survival of 11.2 months in patients with soft tissue sarcoma (PMID: 26970174). | 26970174 |
| Unknown unknown | sarcoma | not applicable | FGFR2 Inhibitor | Pazopanib | FDA approved | Actionable | In a Phase III trial that supported FDA approval, Votrient (pazopanib) improved progression free survival in patients with advanced soft tissue sarcoma (PMID: 22595799). | 22595799 detail... |
| Unknown unknown | leiomyosarcoma | not applicable | FGFR2 Inhibitor | Pazopanib | Clinical Study | Actionable | In a retrospective study, Votrient (pazopanib) treatment resulted in median progression free survival of 18.6 weeks and median survival of 20.1 months in patients with leiomyosarcoma (PMID: 26970174). | 26970174 |
| Unknown unknown | gastrointestinal neuroendocrine tumor | not applicable | FGFR2 Inhibitor | Pazopanib | Clinical Study | Actionable | In a clinical study, Votrient (pazopanib) treatment in patients with gastroenteropancreatic neuroendocrine tumors resulted in an overall response rate of 24% (19/124), stable disease in 39.5% (49/124), a progression free survival of 36% at six months, and a median overall survival of 10.2 months (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 446P). | detail... |
| Unknown unknown | fibrous histiocytoma | not applicable | FGFR2 Inhibitor | Pazopanib | Clinical Study | Actionable | In a retrospective study, Votrient (pazopanib) treatment resulted in median progression free survival of 15.3 weeks and median survival of 9.5 months in patients with undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma (PMID: 26970174). | 26970174 |
| Unknown unknown | gastrointestinal stromal tumor | not applicable | FGFR2 Inhibitor | Pazopanib | Phase II | Actionable | In a Phase II trial, treatment with Votrient (pazopanib) plus best supportive care (BSC) resulted in improved progression-free survival (45% at 4 months) compared to BSC alone (15% at 4 months) in patients with Gleevec (imatinib) and Sutent (sunitinib)-resistant gastrointestinal stromal tumors (J Clin Oncol 33, 2015 (suppl; abstr 10506)). | detail... |
| Unknown unknown | renal cell carcinoma | not applicable | FGFR2 Inhibitor | Pazopanib | Phase III | Actionable | In a Phase III trial, adjuvant Votrient (pazopanib) therapy post nephrectomy did not improve disease-free survival (HR=0.862, p=0.165) compared to placebo in patients with renal cell carcinoma (J Clin Oncol 35, 2017 (suppl; abstr 4507)). | detail... |
| Unknown unknown | renal cell carcinoma | not applicable | FGFR2 Inhibitor | Pazopanib | FDA approved | Actionable | In a Phase III trial that supported FDA approval, Votrient (pazopanib) improved progression free survival in patients with advanced renal cell carcinoma (PMID: 20100962). | 20100962 detail... |
| Unknown unknown | Advanced Solid Tumor | not applicable | FGFR2 Inhibitor | Pazopanib | Phase I | Actionable | In a Phase I trial, Votrient (pazopanib) demonstrated safety and efficacy in a variety of pediatric solid tumors (PMID: 23857966). | 23857966 |
| Unknown unknown | Advanced Solid Tumor | not applicable | FGFR2 Inhibitor | Pazopanib | Phase I | Actionable | In a Phase I study, Votrient (pazopanib) in combination with Taxol (paclitaxel) and Paraplatin (carboplatin) demonstrated efficacy in solid tumors (PMID: 22679111). | 22679111 |
| Unknown unknown | lung non-small cell carcinoma | not applicable | FGFR2 Inhibitor | Pazopanib | Phase II | Actionable | In a Phase II trial, Votrient (pazopanib) treatment resulted in 86% (30/35) of patients with non-small cell lung cancer experiencing a decrease in tumor size, including one patient with a greater than 50% reduction, and resulted in a partial response based on RECIST criteria in three patients (PMID: 20516450). | 20516450 |
| Unknown unknown | uterus leiomyosarcoma | not applicable | FGFR2 Inhibitor | Pazopanib | Clinical Study | Actionable | In a retrospective clinical study, 33% (9/27) of patients with uterine leiomyosarcoma responded to Votrient (pazopanib) treatment (PMID: 29185261). | 29185261 |
| Unknown unknown | liposarcoma | not applicable | FGFR2 Inhibitor | Pazopanib | Clinical Study | Actionable | In a retrospective study, Votrient (pazopanib) treatment resulted in median progression free survival of 8 weeks and median survival of 7.3 months in patients with liposarcoma (PMID: 26970174). | 26970174 |
| Unknown unknown | germ cell cancer | not applicable | FGFR2 Inhibitor | Pazopanib | Phase II | Actionable | In a Phase II trial, Votrient (pazopanib) treatment resulted in partial responses in 4.7% (2/43), stable disease in 44.2% (19/43), and a 3-month progression free survival probability of 12.8% in patients with refractory germ cell cancer (PMID: 28383677). | 28383677 |
| Unknown unknown | synovial sarcoma | not applicable | FGFR2 Inhibitor | Pazopanib | Clinical Study | Actionable | In a retrospective study, Votrient (pazopanib) treatment resulted in median progression free survival of 16.4 weeks and median survival of 10.6 months in patients with synovial sarcoma (PMID: 26970174). | 26970174 |
| Unknown unknown | clear cell renal cell carcinoma | not applicable | FGFR2 Inhibitor | Pazopanib | Phase II | Actionable | In a Phase II trial, 84% (84/100) of patients with renal clear cell cancer demonstrated a clinical benefit, which included a median tumor reduction of 14.4%, when treated with Votrient (pazopanib) prior to a planned nephrectomy (PMID: 27254750). | 27254750 |
| Unknown unknown | clear cell renal cell carcinoma | not applicable | FGFR2 Inhibitor | Pazopanib | Phase III | Actionable | In a Phase III trial, Votrient (pazopanib) did not result in a significantly improved disease free survival compared to placebo in patients with renal clear cell carcinoma (PMID: 28902533). | 28902533 |
| Unknown unknown | renal cell carcinoma | no benefit | FGFR2 Inhibitor | Pazopanib + Pembrolizumab | Phase I | Actionable | In a Phase I trial, Votrient (pazopanib) and Keytruda (pembrolizumab) combination treatment resulted in significant hepatotoxicity in patients with advanced renal cell carcinoma (J Clin Oncol 35, 2017 (suppl; abstr 4506)). | detail... |
| Unknown unknown | renal cell carcinoma | not applicable | FGFR2 Inhibitor | Pazopanib + Trametinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, combination of Mekinist (trametinib) and Votrient (pazopanib) effectively inhibited tumor angiogenesis and growth in cell line xenograft models of renal cell carcinoma (PMID: 26487278). | 26487278 |
| Unknown unknown | Advanced Solid Tumor | not applicable | FGFR2 Inhibitor | Pazopanib + Trametinib | Phase I | Actionable | In a Phase I trial, combination treatment with Votrient (pazopanib) and Mekinist (trametinib) was tolerable and resulted in partial response in 12% (3/25), and stable disease in 72% (18/25) of patients with advanced solid tumors, and 9 patients remained on study for more than 6 cycles, including patients with differentiated thyroid cancer (n=3), colorectal cancer (n=2), melanoma (n=1), cholangiocarcinoma (n=1), ovarian cancer (n=1), and synovial cell sarcoma (n=1) (PMID: 31186313; NCT01438554). | 31186313 |
| Unknown unknown | differentiated thyroid gland carcinoma | not applicable | FGFR2 Inhibitor | Pazopanib + Trametinib | Phase I | Actionable | In a Phase I trial, treatment with the combination of Votrient (pazopanib) and Mekinist (trametinib) was tolerable and resulted in an objective response rate of 33% (4/12, all partial responses), stable disease in 50% (5/12), a median progression-free survival (PFS) of 10.7 months, a 2-year PFS of 25%, and a median overall survival of 29.3 months in patients with differentiated thyroid cancer in the dose expansion cohort (PMID: 31186313; NCT01438554). | 31186313 |
| Unknown unknown | sarcoma | no benefit | FGFR2 Inhibitor | Pazopanib + Trametinib | Phase Ib/II | Actionable | In a Phase Ib/II trial, the combination of Votrient (pazopanib) and Mekinist (trametinib) demonstrated safety and resulted in partial response in 8% (2/25) and stable disease in 48% (12/25) of patients with advanced soft tissue sarcomas, but did not improve the 4 month progression-free survival rate over Votrient (pazopanib) alone (PMID: 28377484). | 28377484 |
| Unknown unknown | Advanced Solid Tumor | not applicable | FGFR2 Inhibitor | Derazantinib | Phase I | Actionable | In a Phase I trial, Derazantinib (ARQ 087) treatment resulted in partial response in 4.5% (3/67) and stable disease in 38.8% (26/67) of patients with advanced solid tumors (PMID: 28972963; NCT01752920). | 28972963 |
| Unknown unknown | multiple myeloma | not applicable | FGFR2 Inhibitor | INCB054329 + Pemigatinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with the combination of INCB054329 and Pemazyre (pemigatinib) decreased MYC expression and FGFR3 signaling and inhibited tumor growth in a t(4;14)-positive myeloma cell line xenograft model, demonstrating increased efficacy over either agent alone (PMID: 30206163). | 30206163 |
| Unknown unknown | colorectal cancer | not applicable | FGFR2 Inhibitor | Navitoclax + TAK-901 | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of TAK-901 and ABT-263 demonstrated synergy in inhibiting proliferation of colorectal cancer cell lines in culture (PMID: 25667100). | 25667100 |
| Unknown unknown | lung non-small cell carcinoma | not applicable | FGFR2 Inhibitor | Navitoclax + TAK-901 | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of TAK-901 and Navitoclax (ABT-263) resulted in a synergistic effect, demonstrating reduced cell viability of non-small cell lung cancer cells in culture (PMID: 28179288). | 28179288 |
| Unknown unknown | prostate cancer | not applicable | FGFR2 Inhibitor | Navitoclax + TAK-901 | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of TAK-901 and Navitoclax (ABT-263) resulted in a synergistic effect, demonstrating reduced cell viability of prostate cancer cells in culture (PMID: 28179288). | 28179288 |
| Unknown unknown | malignant pleural mesothelioma | no benefit | FGFR2 Inhibitor | AZD4547 | Phase II | Actionable | In a Phase II trial, AZD4547 treatment resulted in progression-free survival at 6 months (PFS6) in 12% (3/24) of patients with malignant pleural mesothelioma, which did not achieve the required PFS6 for continuation to stage 2 and the trial was discontinued (PMID: 31901768). | 31901768 |
| Unknown unknown | urinary bladder cancer | not applicable | FGFR2 Inhibitor | AZD4547 + Cisplatin + Gemcitabine | Phase I | Actionable | In a Phase I trial, AZD4547 in combination with Platinol (cisplatin) and Gemzar (gemcitabine) demonstrated safety and preliminary efficacy in bladder cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 4521)). | detail... |
| Unknown unknown | breast cancer | not applicable | FGFR2 Inhibitor | Lucitanib | Phase II | Actionable | In a Phase II trial, Lucitanib (E-3810) demonstrated acceptable toxicity and activity, resulted in a median progression-free survival of 3.5 and 2.6 months for 10mg and 15mg treatment groups respectively, with no differences in response correlated with FGFR1 and 11q amplification status in metastatic breast cancer patients (Cancer Res 2017;77(4 Suppl):Abstract nr P6-11-03). | detail... |
| Unknown unknown | triple-receptor negative breast cancer | not applicable | FGFR2 Inhibitor | Lucitanib | Preclinical | Actionable | In a preclinical study, Lucitanib (E-3810) demonstrated antitumor activity in mouse xenograft models of triple negative breast cancer with synergistic effects noted when using Lucatinib plus chemotherapy (PMID: 23270924). | 23270924 |
| Unknown unknown | colon carcinoma | not applicable | FGFR2 Inhibitor | Bevacizumab + S-49076 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, S-49076, in combination with Avastin (bevacizumab) arrested tumor growth in cell line xenograft models of colon carcinoma with previous resistance to Avastin (bevacizumab) (PMID: 23804704). | 23804704 |
| Unknown unknown | Advanced Solid Tumor | not applicable | FGFR2 Inhibitor | S-49076 | Phase I | Actionable | In a Phase I trial, S-49076 demonstrated safety and limited preliminary clinical activity in patients with advanced solid tumors, resulting in stable disease as best response in 50% of patients, with 23% demonstrating stable disease for at least 3 months, and 9 patients demonstrating stable disease for at least 6 months (PMID: 28624695). | 28624695 |
| Unknown unknown | Advanced Solid Tumor | not applicable | FGFR2 Inhibitor | E7090 | Phase I | Actionable | In a Phase I trial, treatment with E7090 demonstrated safety and was well-tolerable in advanced solid tumor patients (N=24), and led to one partial response and stable disease in seven patients (PMID: 31797489; NCT02275910). | 31797489 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|